Gleevec is the registered trade name for Imatinib, a specific inhibitor of tyrosine kinase BCR-ABL. BCR-ABL is a fusion protein created by the Philadelphia Chromosome abnormality that characterizes chronic myeloid leukemia (CML).
The oral prescription dose of Gleevec is marketed by Novartis Pharmaceuticals.
According to the company, the drug has demonstrated effective action against Chronic Myeloid Leukemia in children.
The company also claims that the sublingual formulation with taste masking features makes the drug acceptable in taste for the children with chronic dosage requirements.